SCHEMBL1588028

SCHEMBL1588028

c1ccc(CN2CCC3(CC2)COCc2ccccc23)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 19/20 0.66
TP53 P04637 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP3A4 P08684 2/20 0.66
CYP2D6 P10635 2/20 0.66
TSHR P16473 2/20 0.66
CYP2C19 P33261 2/20 0.66
ALDH1A1 P00352 1/20 0.66
CYP2C9 P11712 1/20 0.66
DRD2 P14416 2/20 0.63
HTR2A P28223 2/20 0.63
HTR2C P28335 2/20 0.63
HTR2B P41595 2/20 0.63
NFKB1 P19838 1/20 0.63
MAPK1 P28482 1/20 0.63
MTOR P42345 1/20 0.63
MEN1 O00255 1/20 0.61
BLM P54132 1/20 0.61
PMP22 Q01453 1/20 0.61
KMT2A Q03164 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7436502 0.83 SIGMAR1 (0.56) SIGMAR1
SCHEMBL8553726 0.83 SIGMAR1 (0.56) SIGMAR1
SCHEMBL466954 0.80 SIGMAR1 (1.00) SIGMAR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL19828185 0.78 SIGMAR1 (0.33) SIGMAR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL29793198 0.78 SIGMAR1 (0.33) SIGMAR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL4206840 0.77 SIGMAR1 (0.80) SIGMAR1
SCHEMBL29802790 0.77 SIGMAR1 (1.00) SIGMAR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL1587952 0.77 SIGMAR1 (0.57) SIGMAR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL467191 0.77 SIGMAR1 (1.00) SIGMAR1TP53CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL2882074 0.76 SIGMAR1 (0.78) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-55139381-A None JP disclosed
US-20110092529-A1 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists PFIZER INC. 2011-04-21 US disclosed
US-6207677-B1 ADMINISERING SIGMA RECEPTOR BINDING PIPERIDINE DERIVATIVE FOR TREATING ANXIETY, EPILEPSY, CONVULSION, MOVEMENT DISORDER, AMNESIA H. LUNDBECK A/S (DK) 2001-03-27 US disclosed
US-6090808-A PSYCHOLOGICAL DISORDERS; ANTICONVULSANTS H. LUNDBECK A/S (DK) 2000-07-18 US disclosed
US-6031099-A Piperidine derivates having anxiolytic effect H. LUNDBECK A/S (DK) 2000-02-29 US disclosed
EP-0593511-B1 PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT LUNDBECK & CO AS H (DK) 1998-09-02 EP disclosed
EP-0859004-A1 Piperidine derivatives having anxiolytic effect H. LUNDBECK A/S (DK) 1998-08-19 EP disclosed
EP-0649407-B1 DIMERIC PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES LUNDBECK & CO AS H (DK) 1998-08-05 EP disclosed
EP-0853085-A1 Piperidine derivatives having anxiolytic effect H. LUNDBECK A/S (DK) 1998-07-15 EP disclosed
US-5665725-A Piperidine derivatives having anxiolytic effect Lundbeck, H. (DK) 1997-09-09 US disclosed
US-5658921-A POTENT SIGMA RECEPTOR LIGANDS; WATER SOLUBILITY; SYMMETRY H. LUNDBECK A/S (DK) 1997-08-19 US disclosed
EP-0649407-A1 DIMERIC PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES H. LUNDBECK A/S (DK) 1995-04-26 EP disclosed
EP-0593511-A1 PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT H. LUNDBECK A/S (DK) 1994-04-27 EP disclosed
WO-1993025527-A1 DIMERIC PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES H. LUNDBECK A/S (DK) 1993-12-23 WO disclosed
WO-1992022554-A1 PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT H. LUNDBECK A/S (DK) 1992-12-23 WO disclosed
EP-0518805-A1 Piperidine derivatives H. LUNDBECK A/S (DK) 1992-12-16 EP disclosed
JP-S55139381-A SPIROISOCHROMAN DAI ICHI SEIYAKU CO LTD 1980-10-31 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092529-A1 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists OXTR, PRLHR, KISS1R SIGMAR1 748/4885TP53 4827/4885CYP1A2 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.